Open AccessThis article is
- freely available
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes
Department of Biochemistry, University of Puerto Rico, San Juan, Puerto Rico 00935, USA
Comprehensive Cancer Center & Department of Biochemistry, University of Puerto Rico, San Juan, Puerto Rico 00935, USA
* Author to whom correspondence should be addressed.
Received: 12 September 2013; in revised form: 24 October 2013 / Accepted: 28 October 2013 / Published: 4 November 2013
Abstract: Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery, and therapeutic effectiveness of several anticancer agents. The expansion of novel nanoparticles for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies, including small interference RNA (siRNA) and microRNA (miRNAs)-based molecules. In this review, we focus on the currently available drug delivery systems for anticancer agents. In addition, we will discuss the promising use of nanoparticles for novel cancer treatment strategies.
Keywords: nanoparticles; nanoliposomes; RNAi; miRNA; siRNA
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Díaz, M.R.; Vivas-Mejia, P.E. Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. Pharmaceuticals 2013, 6, 1361-1380.
Díaz MR, Vivas-Mejia PE. Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. Pharmaceuticals. 2013; 6(11):1361-1380.
Díaz, Mónica R.; Vivas-Mejia, Pablo E. 2013. "Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes." Pharmaceuticals 6, no. 11: 1361-1380.